CA2363933C - Capsule system - Google Patents

Capsule system Download PDF

Info

Publication number
CA2363933C
CA2363933C CA002363933A CA2363933A CA2363933C CA 2363933 C CA2363933 C CA 2363933C CA 002363933 A CA002363933 A CA 002363933A CA 2363933 A CA2363933 A CA 2363933A CA 2363933 C CA2363933 C CA 2363933C
Authority
CA
Canada
Prior art keywords
active ingredient
capsule
capsule system
vehicle
tazarotene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002363933A
Other languages
English (en)
French (fr)
Other versions
CA2363933A1 (en
Inventor
Bruce A. Firestone
Thao T. Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2363933A1 publication Critical patent/CA2363933A1/en
Application granted granted Critical
Publication of CA2363933C publication Critical patent/CA2363933C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002363933A 1999-03-04 2000-03-03 Capsule system Expired - Fee Related CA2363933C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/262,623 US6248354B1 (en) 1999-03-04 1999-03-04 Capsule system
US09/262,623 1999-03-04
PCT/US2000/005811 WO2000051571A2 (en) 1999-03-04 2000-03-03 Capsule system

Publications (2)

Publication Number Publication Date
CA2363933A1 CA2363933A1 (en) 2000-09-08
CA2363933C true CA2363933C (en) 2006-07-11

Family

ID=22998308

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002363933A Expired - Fee Related CA2363933C (en) 1999-03-04 2000-03-03 Capsule system

Country Status (7)

Country Link
US (3) US6248354B1 (enExample)
EP (1) EP1158965A2 (enExample)
JP (1) JP2002538098A (enExample)
AU (1) AU768796B2 (enExample)
CA (1) CA2363933C (enExample)
HK (1) HK1042241A1 (enExample)
WO (1) WO2000051571A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7115277B2 (en) * 1999-03-04 2006-10-03 Allergan, Inc. Method for enabling delivery of an active agent
US6457471B1 (en) 2000-06-30 2002-10-01 Medihale Ltd. Dual-purpose medical device for upper airway treatment and methods for using same
US7604812B2 (en) * 2000-12-15 2009-10-20 Patrick Franke Hypoallergenic and non-irritant skin care formulations
US6752953B2 (en) * 2001-12-03 2004-06-22 Yung Shin Pharmaceutical Co., Ltd. Method for manufacturing hard non-gelatin pharmaceutical capsules
US7314643B2 (en) * 2002-08-20 2008-01-01 Nikken Chemicals Co., Ltd. Soft capsule preparation
EP1527774A1 (en) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
CA2534008A1 (en) * 2003-07-30 2005-02-10 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoid components
US20050026949A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoids without regard to body weight
US20050026950A1 (en) * 2003-07-30 2005-02-03 Allergan, Inc. Methods of therapeutic treatment using retinoids to achieve consistent bioavailability
CA2534005A1 (en) * 2003-07-30 2005-02-10 Allergan, Inc. Methods of therapeutic treatment using amounts of retinoid components
US20060020037A1 (en) * 2004-07-22 2006-01-26 Allergan, Inc. Tazarotenic acid and esters thereof for treating autism
EP1876914A2 (en) * 2005-04-04 2008-01-16 Archer-Daniels-Midland Company Lignan-containing compositions
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
BRPI1008037B1 (pt) * 2009-02-25 2019-08-06 Stiefel Research Australia Pty Ltd. Composição de espuma aerossol de emulsão de óleo em água, uso da dita composição para o tratamento de uma doença, distúrbio ou condição da pele e processo para a preparação da dita composição
WO2010134048A2 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Topical retinoid solutions
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
GB2488788B (en) 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
BR112014032948A2 (pt) * 2012-07-02 2017-06-27 Dsm Ip Assets Bv cápsulas contendo timoquinona
JP7728653B2 (ja) * 2021-04-05 2025-08-25 真 小林 内視鏡用処置具

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2960M (fr) * 1962-03-30 1964-11-30 Pfizer & Co C Compositions, facilement dispersibles dans l'eau, a base d'ester d'acide gras de vitamine a.
JPS58128141A (ja) * 1982-01-26 1983-07-30 Sumitomo Chem Co Ltd 自己乳化分散型カロチノイド類含有ソフトカプセル剤の製法
US4612194A (en) 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
JPH0426670A (ja) * 1990-05-18 1992-01-29 Nisshin Flour Milling Co Ltd 安定化された油溶性ビタミン含有組成物
US5965160A (en) * 1995-04-24 1999-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system

Also Published As

Publication number Publication date
WO2000051571B1 (en) 2001-05-25
AU768796B2 (en) 2004-01-08
US6656500B2 (en) 2003-12-02
JP2002538098A (ja) 2002-11-12
AU3726600A (en) 2000-09-21
US6248354B1 (en) 2001-06-19
US20040115257A1 (en) 2004-06-17
HK1042241A1 (zh) 2002-08-09
CA2363933A1 (en) 2000-09-08
WO2000051571A3 (en) 2001-02-15
WO2000051571A2 (en) 2000-09-08
EP1158965A2 (en) 2001-12-05
US20010016206A1 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
CA2363933C (en) Capsule system
ES2592504T3 (es) Preparaciones de liberación controlada
US11766445B2 (en) Oral soft gel capsule containing psychedelic compound
EP3280448B1 (en) Abiraterone acetate lipid formulations
ES2703731T3 (es) Cápsulas de gel blando multifase, aparatos y método de estos
RU2121344C1 (ru) Лекарственная форма двухфазного действия с высвобождением для липофильных лекарственных препаратов и способ ее получения
US5595758A (en) Soft-shelled gelatin encapsulated particles
CN105188670B (zh) 乳液制剂
EA006141B1 (ru) Приготовление эмульсий витаминов и их концентратов
JPH09503495A (ja) 高濃度アセトアミノフェン溶液含有ゼラチンカプセル
CN102470103A (zh) 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
AU2024205054A1 (en) Cannabidiol orally disintegrating tablets
KR20030018083A (ko) 이트라코나졸을 함유하는 조성물 및 그 제조방법
CN102802729A (zh) 异维a酸的液体剂型
WO2009069139A1 (en) Dosage form providing an ibuprofen-containing liquid fill
KR20110022586A (ko) 인돌리논 유도체의 즉시 방출용 약제학적 투여형
EP0152292A2 (en) Acetaminophen gelatin capsules
NL9000428A (nl) Farmaceutische samenstellingen.
EP1005346A2 (en) Solutions containing azasteroids
AU2021103957A4 (en) A composition and application thereof
US7115277B2 (en) Method for enabling delivery of an active agent
WO2009113086A2 (en) Ibuprofen liquid fill formulation, dosage form thereof and a process for its preparation
RU2108787C1 (ru) Фармацевтические мягкие капсулы, содержащие лизинхлониксинат, способ их получения
Lippert Investigations into fed-state effects on phenytoin absorption and pharmacokinetics in dogs
Hutchison Encapsulation in Softgels for Pharmaceutical Advantage

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed